Deferasirox dosing
| . | Deferasirox cohort (n = 296) . | Crossover cohort (n = 259) . | All patients (n = 555) . |
|---|---|---|---|
| Patients in planned dose groups at start of deferasirox, n (%) | |||
| < 15 mg/kg/d | 92 (31.1) | 104 (40.2) | 196 (35.3) |
| 15 to < 25 mg/kg/d | 85 (28.7) | 94 (36.3) | 179 (32.3) |
| 25 to < 35 mg/kg/d | 119 (40.2) | 58 (22.4) | 177 (31.9) |
| ≥ 35 mg/kg/d | 0 | 3 (1.16) | 3 (0.54) |
| Patients in final actual dose groups, n (%) | |||
| < 15 mg/kg/d | 43 (14.5) | 13 (5.0) | 56 (10.1) |
| 15 to < 25 mg/kg/d | 113 (38.2) | 100 (38.6) | 213 (38.4) |
| 25 to < 35 mg/kg/d | 108 (36.5) | 101 (39.0) | 209 (37.7) |
| ≥ 35 mg/kg/d | 32 (10.8) | 45 (17.4) | 77 (13.9) |
| . | Deferasirox cohort (n = 296) . | Crossover cohort (n = 259) . | All patients (n = 555) . |
|---|---|---|---|
| Patients in planned dose groups at start of deferasirox, n (%) | |||
| < 15 mg/kg/d | 92 (31.1) | 104 (40.2) | 196 (35.3) |
| 15 to < 25 mg/kg/d | 85 (28.7) | 94 (36.3) | 179 (32.3) |
| 25 to < 35 mg/kg/d | 119 (40.2) | 58 (22.4) | 177 (31.9) |
| ≥ 35 mg/kg/d | 0 | 3 (1.16) | 3 (0.54) |
| Patients in final actual dose groups, n (%) | |||
| < 15 mg/kg/d | 43 (14.5) | 13 (5.0) | 56 (10.1) |
| 15 to < 25 mg/kg/d | 113 (38.2) | 100 (38.6) | 213 (38.4) |
| 25 to < 35 mg/kg/d | 108 (36.5) | 101 (39.0) | 209 (37.7) |
| ≥ 35 mg/kg/d | 32 (10.8) | 45 (17.4) | 77 (13.9) |